Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedRevision v3.3.2 has been added to the Record History, and Revision v3.2.0 has been removed from the list.SummaryDifference0.1%

- Check20 days agoChange DetectedThe banner about a lapse in government funding and operating status (with references to cc.nih.gov and opm.gov) was removed. This is a site-wide notice rather than a change to the trial record details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check34 days agoChange DetectedVersion 5 (2023-03-07) was added to the history, updating Recruitment Status, Study Status, and Study Design. This revision reflects the trial's current activity and design details.SummaryDifference0.1%

- Check63 days agoChange Detected- Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.SummaryDifference12%

- Check70 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No other substantive content changes are indicated.SummaryDifference0.3%

- Check84 days agoChange DetectedThe page version updated from v3.0.1 to v3.0.2, signaling a minor content update; the 'Back to Top' link was removed, a minor UI change.SummaryDifference0.7%

Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.